The European Medicines Agency’s Committee for Medicinal Products for Human Use found that Leqembi’s benefits do not outweigh the risks of severe side effects associated with the treatment.
EU regulators reject Leqembi for Alzheimers
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $70.90M | |||
| Open | High | Low | Value | Volume |
| 2.3¢ | 2.4¢ | 2.3¢ | $44.25K | 1.881M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 2727066 | 2.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.4¢ | 526273 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| ACW (ASX) Chart |